Modulatory role of resveratrol on cytotoxic activity of cisplatin, sensitization and modification of cisplatin resistance in colorectal cancer cells

Molecular Medicine Reports

Volumn 12, Issue 1, 2015, Pages 1368-1374

  Osman, Abdel Moneim M ^a,b   Al Malki, Hamdan S ^a   Al Harthi, Sameer E ^a   El Hanafy, Amr A ^c,d   Elashmaoui, Hassan M ^c,e   Elshal, Mohamed F ^c,f  

^a King Abdulaziz University   (Saudi Arabia)

^b CAIRO UNIVERSITY   (Egypt)

^c KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^d GENETIC ENGINEERING AND BIOTECHNOLOGY RESEARCH INSTITUTE   (Egypt)

^e NATIONAL RESEARCH CENTRE   (Egypt)

^f MENOUFIA UNIVERSITY   (Egypt)

Author keywords

Cisplatin; Colorectal cancer; Interaction; Resveratrol

Indexed keywords

CISPLATIN; POLYPHENOL; RESVERATROL; ANTIOXIDANT; STILBENE DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; COLON CARCINOGENESIS; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DRUG ISOLATION; DRUG SENSITIZATION; DRUG UPTAKE; HCT116 CELL LINE; HUMAN; HUMAN CELL; IC50; MINIMUM INHIBITORY CONCENTRATION; PLANT ROOT; VERATRUM; VERATRUM GRANDIFLORUM; CARCINOGENESIS; CELL CYCLE; COLORECTAL NEOPLASMS; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; PATHOLOGY;

HELLEBORUS; VERATRUM GRANDIFLORUM;

ANTIOXIDANTS; APOPTOSIS; CARCINOGENESIS; CELL CYCLE; CISPLATIN; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; HCT116 CELLS; HUMANS; STILBENES;

EID: 84926612664     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.3513     Document Type: Article

References (30)

1. Ibrahim EM, Zeeneldin AA, El-Khodary TR, Al-Gahmi AM and Bin Sadiq BM: Past, present and future of colorectal cancer in the Kingdom of Saudi Arabia. Saudi J Gastroenterol 14: 178-182, 2008.
2. Al-Ahwal MS, Shafik YH and Al-Ahwal HM: First national survival data for colorectal cancer among Saudis between 1994 and 2004: what's next? BMC Public Health 13: 73, 2013.
3. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S and Takada Y: Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 24: 2783-2840, 2004.
4. Taguchi T, Nazneen A, Abid MR and Razzaque MS: Cisplatin-associated nephrotoxicity and pathological events.Contrib Nephol 148: 107-121, 2005.
5. al-Harbi MM, Osman AM, al-Gharably AM, et al: Effect of desferrioxamine on cisplatin-induced nephotoxicity in normal rats. Chemotherapy 41: 448-454, 1995.
6. Osman AM, Al-sedairy ST and Moran IM: Verapamil enhancement of antitumour effect of cisdiamminodichloroplatin (II) in mouse bearing ehlich ascites carcinoma cells. Med Sci Res 24: 429-431, 1996.
7. Osman AM, Mohamed MA, Abdel-Wahab AA, and Ahmed MS: Modulation by verapamil of doxorubicin induced expression of multidrug resistance gene (mdr-1/P-glycoprotein) in murine tumour cells. J Egypt Nat Cancer Inst 12: 221-227, 2000.
8. Arafa HM, Abdel-Hamid MA, El-Khouly AA, Elmazar MM, and Osman AM: Enhancement by dexamethasone of the therapeutic benefits of cisplatin via regulation of tumor angiogenesis and cell cycle kinetics in a murine tumor paradigm. Toxicology 222: 103-113, 2006.
9. Baur JA and Sinclair DA: Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5: 493-506, 2006.
10. Skehan P, Storeng R, Scudiero D, et al: New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107-1112, 1990.
11. Kuypers FA, Lewis RA, Hua M, Schott MA, Discher D, Ernst JD and Lubin BH: Detection of altered membrane phospholipid asymmetry in subpopulations of human red blood cells using fluorescently labeled annexin V. Blood 187: 1179-87, 1996.
12. Pozarowski P and Darzynkiewicz Z: Analysis of cell cycle by flow cytometry. Methods Mol Biol 281: 301-311, 2004.
13. Shi L, Nishioka WK, Th'ng J, Bradbury EM, Litchfield DW and Greenberg AH: Premature p34cdc2 activation required for apoptosis. Science 263: 1143-1145, 1994.
14. Shapiro GI and Harper JW: Anticancer drug targets: cell cycle and checkpoint control. J Clin Invest 104: 1645-1653, 1999.
15. Wang D and Lippard SJ: Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4: 307-320, 2005.
16. Ciccarelli RB, Solomon MJ, Varshavsky A and Lippard SJ: In vivo effects of cis-and trans-diamminedichloroplatinum(II) on SV40 chomosomes: differential repair, DNA-protein cross-linking, and inhibition of replication. Biochemistry 24: 7533-7540, 1985.
17. Eastman A: The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol Ther 34: 155-166, 1987.
18. Brabec V and Kasparkova J: Modifications of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs. Drug Resist Updat 8: 131-146, 2005.
19. Florea AM and Büsselberg D: Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel) 3: 1351-1371, 2011.
20. Kartalou M. and Essigmann JM: Mechanisms of resistance to cisplatin. Mutat Res 478, 23-43, 2001.
21. Ho GT, Moodie FM and Satsangi J: Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? Gut 52: 759-766, 2003.
22. Gupta SC, Kannappan R, Reuter S, Kim JH and Aggarwal BB Chemosensitization of tumors by resveratrol. Ann NY Acad Sci 1215: 150-160, 2011.
23. Kool M, de Haas M, Scheffer GL, et al: Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 57: 3537-3547, 1997.
24. Tanida S, Mizoshita T, Ozeki K, et al: Mechanisms of cisplatin-induced apoptosis and of cisplatin sensitivity: potential of BIN1 to act as a potent predictor of cisplatin sensitivity in gastric cancer treatment. Int J Surg Oncol 2012: 862879, 2012.
25. Al-Abd AM, Mahmoud AM, El-Sherbiny GA, et al: Resveratrol enhances the cytotoxic profile of docetaxel and doxorubicin in solid tumour cell lines in vitro. Cell Prolif 44: 591-601, 2011.
26. Rezk YA, Balulad SS, Keller RS and Bennett JA: Use of resveratrol to improve the effectiveness of cisplatin and doxorubicin: study in human gynecologic cancer cell lines and in rodent heart. Am J Obstet Gynecol 194: e23-e26, 2006.
27. Wang Y, Romigh T, He X, et al: Resveratrol regulates the PTEN/AKT pathway though androgen receptor-dependent and-independent mechanisms in prostate cancer cell lines. Hum Mol Genet 19: 4319-4329, 2010.
28. Chaudhary PM and Roninson IB: Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 85: 632-639, 1993.
29. Herzog C, Tsokos M, Bates SE and Fojo AT: Increased mdr-1/P-glycoprotein expression after treatment of human colon carcinoma cells with P-glycoprotein antagonists. J Biol Chem 268: 2946-2952, 1993.
30. Fernández de Mattos S, Villalonga P, Clardy J, and Lam EW: FOXO3a mediates the cytotoxic effects of cisplatin in colon cancer cells. Mol Cancer Ther 7: 3237-3246, 2008.